Your browser is no longer supported. Please, upgrade your browser.
Settings
HRTX [NASD]
Heron Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.52 Insider Own0.20% Shs Outstand98.46M Perf Week4.54%
Market Cap1.13B Forward P/E- EPS next Y-1.64 Insider Trans-1.36% Shs Float79.80M Perf Month-10.03%
Income-234.10M PEG- EPS next Q-0.61 Inst Own- Short Float33.70% Perf Quarter-15.35%
Sales83.00M P/S13.58 EPS this Y0.00% Inst Trans-0.01% Short Ratio21.08 Perf Half Y-38.25%
Book/sh1.63 P/B6.50 EPS next Y33.60% ROA-64.20% Target Price- Perf Year-31.66%
Cash/sh2.42 P/C4.37 EPS next 5Y47.50% ROE-107.70% 52W Range9.98 - 22.40 Perf YTD-49.96%
Dividend- P/FCF- EPS past 5Y3.20% ROI-93.70% 52W High-52.72% Beta1.35
Dividend %- Quick Ratio3.90 Sales past 5Y- Gross Margin51.50% 52W Low6.11% ATR0.49
Employees223 Current Ratio4.50 Sales Q/Q-1.30% Oper. Margin- RSI (14)41.16 Volatility3.45% 4.80%
OptionableYes Debt/Eq0.93 EPS Q/Q-1.90% Profit Margin- Rel Volume0.58 Prev Close10.69
ShortableYes LT Debt/Eq0.93 EarningsAug 09 BMO Payout- Avg Volume1.28M Price10.59
Recom1.80 SMA20-6.03% SMA50-6.92% SMA200-29.78% Volume742,239 Change-0.94%
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jan-03-18Initiated Leerink Partners Outperform $22
Sep-27-17Initiated Northland Capital Outperform $40
Feb-27-17Initiated Needham Buy $28
Oct-26-16Initiated Aegis Capital Buy
Sep-06-16Resumed Lake Street Buy $45
May-03-16Initiated Cantor Fitzgerald Buy
Dec-10-15Initiated Lake Street Buy $45
Sep-23-15Reiterated Leerink Partners Outperform $38 → $57
Sep-02-15Initiated BofA/Merrill Buy $46
Aug-03-15Reiterated Brean Capital Buy $40 → $45
Jun-30-15Reiterated JMP Securities Mkt Outperform $25 → $33
Jun-19-15Reiterated Leerink Partners Outperform $26 → $38
Aug-07-14Initiated Noble Financial Buy $18
Oct-11-21 10:00AM  
Oct-04-21 08:30AM  
Sep-21-21 04:05PM  
Sep-13-21 07:33PM  
Aug-15-21 03:35AM  
Aug-09-21 09:15AM  
08:00AM  
Jul-31-21 05:44AM  
Jul-28-21 04:05PM  
03:03PM  
Jul-21-21 04:05PM  
Jul-06-21 08:30AM  
Jul-01-21 08:30AM  
Jun-02-21 01:00PM  
May-25-21 04:05PM  
09:00AM  
May-13-21 10:22AM  
08:00AM  
May-10-21 03:33PM  
09:45AM  
08:30AM  
Apr-28-21 12:33PM  
Apr-22-21 03:47AM  
Apr-07-21 08:38AM  
Mar-26-21 02:34PM  
Feb-24-21 08:30AM  
Feb-21-21 03:24AM  
Feb-17-21 04:05PM  
Jan-21-21 08:30AM  
Jan-11-21 08:30AM  
Dec-29-20 08:57AM  
Dec-23-20 01:46AM  
Dec-19-20 01:06PM  
Nov-13-20 08:30AM  
Nov-11-20 04:05PM  
Nov-08-20 08:06AM  
Nov-05-20 08:30AM  
Nov-03-20 12:30PM  
Oct-23-20 02:05PM  
Oct-14-20 08:10AM  
Oct-06-20 05:05PM  
Sep-29-20 11:42AM  
Sep-28-20 08:30AM  
Sep-16-20 08:30AM  
Sep-11-20 04:05PM  
Sep-09-20 10:19AM  
Sep-08-20 08:30AM  
Aug-29-20 10:23AM  
Aug-12-20 01:00AM  
Aug-05-20 06:35PM  
Aug-04-20 11:26AM  
Jul-27-20 12:31PM  
Jul-24-20 10:29AM  
Jul-16-20 08:30AM  
Jul-02-20 10:38PM  
Jul-01-20 02:26PM  
Jun-30-20 11:15AM  
Jun-29-20 08:47AM  
08:45AM  
Jun-26-20 08:28AM  
Jun-23-20 07:51PM  
Jun-21-20 02:53PM  
Jun-16-20 10:00AM  
Jun-04-20 09:00AM  
May-20-20 10:04AM  
May-18-20 09:00AM  
May-09-20 08:00AM  
May-08-20 10:04AM  
May-06-20 10:35AM  
09:00AM  
May-05-20 07:31AM  
Apr-19-20 07:02AM  
Apr-09-20 04:05PM  
Apr-07-20 03:33PM  
Apr-05-20 09:57AM  
Mar-02-20 09:05AM  
07:30AM  
Feb-27-20 01:19PM  
08:42AM  
Feb-26-20 04:42PM  
Feb-21-20 12:30PM  
Feb-20-20 07:06AM  
Feb-19-20 06:16PM  
Feb-18-20 04:05PM  
Jan-27-20 11:01AM  
Jan-22-20 08:53AM  
Jan-13-20 08:30AM  
Dec-21-19 08:27AM  
Dec-16-19 04:05PM  
Dec-12-19 01:44PM  
Dec-10-19 05:18AM  
Dec-06-19 08:00AM  
Dec-03-19 07:30AM  
Nov-26-19 04:05PM  
Nov-25-19 09:13AM  
Nov-22-19 03:22PM  
Nov-15-19 09:00AM  
08:24AM  
Nov-14-19 04:05PM  
Nov-13-19 04:05PM  
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Christian WaageDirectorSep 21Sale12.313003,6923,500Sep 23 04:30 PM
Johnson Craig ADirectorSep 21Sale12.302503,0743,090Sep 23 04:29 PM
Christian WaageDirectorJun 21Sale15.203004,5593,800Jun 22 05:06 PM
Johnson Craig ADirectorJun 21Sale15.202503,8013,340Jun 22 05:05 PM
MANHARD KIMBERLYEVP, Drug DevelopmentMay 03Sale17.661,52927,0091,634May 04 06:03 PM
Christian WaageDirectorApr 15Sale17.513005,2544,100Apr 16 08:59 PM
Johnson Craig ADirectorApr 06Sale17.222504,3053,590Apr 07 05:04 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 14Sale18.0982714,9600Jan 15 04:30 PM
Szekeres David LeslieEVP, Chief Operating OfficerJan 08Sale19.663,57170,2190Jan 08 06:07 PM
MANHARD KIMBERLYEVP, Drug DevelopmentDec 22Option Exercise13.0010,000130,00010,000Dec 23 04:23 PM
MANHARD KIMBERLYEVP, Drug DevelopmentDec 22Sale20.0010,000200,0000Dec 23 04:23 PM
GOSS Gossamer Bio, Inc. daily Stock Chart
GOSS [NASD]
Gossamer Bio, Inc.
Index- P/E- EPS (ttm)-3.26 Insider Own0.50% Shs Outstand74.67M Perf Week11.93%
Market Cap1.05B Forward P/E- EPS next Y-2.94 Insider Trans0.00% Shs Float67.13M Perf Month33.49%
Income-239.90M PEG- EPS next Q-0.79 Inst Own82.20% Short Float13.80% Perf Quarter94.07%
Sales- P/S- EPS this Y-7.80% Inst Trans0.17% Short Ratio17.54 Perf Half Y68.10%
Book/sh2.96 P/B4.75 EPS next Y5.50% ROA-47.10% Target Price18.43 Perf Year48.26%
Cash/sh5.45 P/C2.58 EPS next 5Y5.20% ROE-80.90% 52W Range7.04 - 14.10 Perf YTD45.50%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-0.21% Beta-
Dividend %- Quick Ratio13.90 Sales past 5Y- Gross Margin- 52W Low99.86% ATR0.67
Employees195 Current Ratio13.90 Sales Q/Q- Oper. Margin- RSI (14)72.57 Volatility4.82% 5.87%
OptionableYes Debt/Eq0.80 EPS Q/Q20.20% Profit Margin- Rel Volume1.09 Prev Close13.51
ShortableYes LT Debt/Eq0.80 EarningsAug 09 AMC Payout- Avg Volume528.38K Price14.07
Recom1.90 SMA2012.99% SMA5032.35% SMA20048.21% Volume575,396 Change4.15%
Sep-21-21Resumed Piper Sandler Overweight $26
Jun-29-20Initiated H.C. Wainwright Buy $31
Apr-22-20Initiated Piper Sandler Overweight $30
Feb-27-20Initiated Barclays Overweight $21
Dec-03-19Resumed BofA/Merrill Buy
Oct-30-19Initiated Berenberg Buy $31
Mar-05-19Initiated SVB Leerink Outperform $30
Mar-05-19Initiated Evercore ISI Outperform $30
Mar-05-19Initiated BofA/Merrill Buy $30
Mar-05-19Initiated Barclays Overweight $27
Oct-11-21 08:36AM  
Oct-07-21 04:01PM  
Oct-03-21 10:45AM  
Sep-21-21 08:31AM  
Aug-09-21 04:01PM  
Aug-02-21 04:01PM  
Jul-21-21 05:16AM  
Jul-17-21 05:47AM  
Jul-07-21 07:01AM  
Jun-21-21 04:01PM  
Jun-14-21 04:01PM  
May-06-21 07:31AM  
Apr-20-21 07:50AM  
Apr-16-21 07:55AM  
Feb-25-21 07:31AM  
Feb-19-21 08:01AM  
Feb-04-21 07:05AM  
Jan-18-21 03:05AM  
Dec-19-20 03:54PM  
Dec-11-20 05:00PM  
Dec-07-20 07:03AM  
Nov-16-20 07:01AM  
Nov-10-20 04:01PM  
02:30PM  
08:00AM  
Nov-06-20 07:07AM  
07:03AM  
Oct-13-20 03:02PM  
07:04AM  
Oct-12-20 08:07AM  
Oct-09-20 08:01AM  
Sep-30-20 08:38AM  
Sep-10-20 07:07AM  
Sep-07-20 11:00AM  
Sep-01-20 04:30PM  
Aug-11-20 04:01PM  
Aug-05-20 08:31AM  
Jul-22-20 12:55PM  
08:12AM  
Jul-03-20 06:27PM  
Jun-08-20 09:00AM  
Jun-02-20 04:25PM  
04:00PM  
03:19PM  
01:57PM  
12:54PM  
12:30PM  
11:40AM  
11:00AM  
10:01AM  
09:21AM  
06:20AM  
Jun-01-20 11:45PM  
06:10PM  
05:25PM  
12:00PM  
11:07AM  
10:00AM  
10:00AM  
07:35AM  
06:20AM  
May-31-20 10:50PM  
12:53PM  
08:30AM  
May-30-20 03:39PM  
03:30PM  
May-29-20 03:40PM  
02:40PM  
01:45PM  
12:50PM  
11:33AM  
10:32AM  
08:07AM  
May-28-20 09:20PM  
08:40PM  
02:55PM  
12:00PM  
11:30AM  
11:02AM  
10:30AM  
06:30AM  
May-27-20 11:25PM  
06:20PM  
04:30PM  
01:40PM  
01:00PM  
11:26AM  
10:22AM  
08:48AM  
07:36AM  
May-26-20 03:10PM  
02:35PM  
01:30PM  
12:52PM  
10:01AM  
09:00AM  
May-25-20 03:20PM  
02:30PM  
02:20PM  
06:20AM  
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giraudo BryanChief Financial OfficerMar 23Sale9.485,49052,046109,889Mar 25 04:11 PM
Salter-Cid LuisaChief Scientific OfficerMar 23Sale9.485,49152,052206,065Mar 25 04:13 PM